MedTrace Logo

Prospective Trial of Tranexamic Acid in Cardiac Surgery

NCT01998438 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 955

Last updated 2016-02-26

Study results available
· View outcomes & findings →

Summary

Tranexamic acid, an antifibrinolytic drug, is wildly used in cardiac surgeries to decrease perioperative bleeding and allogenic transfusion. But the optimum dose of tranexamic acid is still unknown. We use three different doses to find which is the optimum dose of tranexamic acid in cardiopulmonary bypass cardiac surgery.

Conditions

  • C.Surgical Procedure; Cardiac

Interventions

DRUG

Tranexamic Acid

The loading doses were given in 15 minutes when incision.

Sponsors & Collaborators

  • Hongwen Ji

    lead OTHER

Principal Investigators

  • Hongwen Ji, MD · Cardiovascular Institute and Fuwai Hospital, CAMS&PUMC

  • Haisong Lu · Cardiovascular Institute and Fuwai Hospital, CAMS&PUMC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2014-09-30
Completion
2014-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01998438 on ClinicalTrials.gov